Trial reportMultiple sclerosis (Houndmills, Basingstoke, England)2018
The efficacy of teriflunomide in patients who received prior disease-modifying treatments: Subgroup analyses of the teriflunomide phase 3 TEMSO and TOWER studies.
Trial report in Multiple sclerosis (Houndmills, Basingstoke, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Design Study to Evaluate the Efficacy and Safety of Teriflunomide in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects With Multiple Sclerosis With Relapses
A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis
Who cites it
9 citing papers in PubMed.
- Prior treatment status: impact on the efficacy and safety of teriflunomide in multiple sclerosis.BMC neurology · 2020Trial
- Teriflunomide as a therapeutic means for myelin repair.Journal of neuroinflammation · 2023Article
- Real-world outcomes of teriflunomide in relapsing-remitting multiple sclerosis: a prospective cohort study.Journal of neurology · 2022Observational
- Smouldering multiple sclerosis: the 'real MS'.Therapeutic advances in neurological disorders · 2022Review
- Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.Journal of neurology · 2021Article
- Molecular Interventions towards Multiple Sclerosis Treatment.Brain sciences · 2020Review
- Review
- Drug repurposing for neuroregeneration in multiple sclerosis.Neural regeneration research · 2018Article
- Oral teriflunomide in the treatment of relapsing forms of multiple sclerosis: clinical evidence and long-term experience.Therapeutic advances in neurological disorders · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting multiple sclerosis (MS). The objective of this post hoc analysis of the phase 3, pooled TEMSO (NCT00134563) and TOWER (NCT00751881) dataset is to evaluate the effect of teriflunomide treatment on annualised relapse rate and disability worsening across patient subgroups defined according to prior disease-modifying therapy exposure. This analysis provides further supportive evidence for a consistent effect of teriflunomide across a broad range of patients with relapsing MS, including patients who have used and discontinued other disease-modifying therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.